Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years-Reference-Cited by-同舟云学术

Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years

Published:2020-04-08 Issue:6 Volume:20 Page:578-583
ISSN:1444-1586
Container-title:Geriatrics & Gerontology International
language:en
Short-container-title:Geriatr. Gerontol. Int.

Author:

Kinoshita Akiyoshi¹²³^ORCID,Koike Kazuhiko¹²,Mizuno Yusuke¹,Ogata Itsuro⁴,Kobayashi Yutaro⁵,Hasegawa Kiyoshi⁶,Shiraishi Koichi⁷,Yoshida Hideo⁸,Nakata Ryo⁸,Yamada Norie⁹,Yasuda Kiyomi⁹

Affiliation:

1. Division of Gastroenterology and Hepatology The Jikei University Daisan Hospital Tokyo Japan

2. Department of Internal Medicine Sakuragaoka Hospital Shizuoka Japan

3. Department of Internal Medicine Johsai Hospital Tokyo Japan

4. Division of Gastroenterology and Hepatology Kawakita General Hospital Tokyo Japan

5. Kobayashi Naika Clinic Tokyo Japan

6. Hasegawa Naika Clinic Tokyo Japan

7. Division of Gastroenterology Tokai University Tokyo Hospital Tokyo Japan

8. Division of Gastroenterology, Japanese Red Cross Medical Center Tokyo Japan

9. Division of Gastroenterology Kiyokawa Hospital Tokyo Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ggi.13919

Reference30 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

3. The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010

4. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans

5. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematological and Biochemical Changes after Anti-Hepatitis C Virus Therapy in Older Patients;INT J GERONTOL;2024

2. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life;Tropical Medicine and Infectious Disease;2023-11-18

3. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study;Liver International;2023-04-30

4. Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study;PLOS ONE;2023-02-02

5. A case of an elderly patient with chronic hepatitis C exacerbated by chemotherapy for malignant lymphoma and improved by direct-acting antivirals therapy;Kanzo;2022-04-01